 |
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Behavioral abnormalities associated with fragile X syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2008-07-28 00:00:00 |
| Sponsor | Seaside Therapeutics;840 Memorial Drive;Cambridge, Massachusetts, 02139 |
